June 2025 EIPM Director's Memo

Dear Friends & Members of the Englander Institute,

I hope you enjoy reading about our recent departmental accomplishments, including news media coverage of our work, participation in major conferences & meetings, and impressive publications in top-tier journals like The New England Journal of Medicine, Nature Communications, and Science Signalingby a range of EIPM colleagues.

Thank you again for your continued hard work and dedication to our mission.

Sincerely,

Olivier Elemento, Ph.D.


News Coverage & Awards 
Congratulations to our Clinical Director Dr. Cora N. Sternberg on delivering a Keynote address [that earned her a standing ovation!] during the International Kidney Cancer Symposium in Amsterdam on May 3rd! 

"Leveraging Beta and Alpha Emitters in Metastatic CRPC Management. Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer." Dr. Scott T. Tagawa told Cancer Network in a May 6th article. 

Our Chief Research Officer Dr. Bishoy Faltas provided the following Expert Commentary to UroToday: "Spatial Heterogeneity in Expression of Targets of Antibody-Drug Conjugates in Bladder Cancer," on May 7th; "Outcomes of Neoadjuvant Chemotherapy in Invasive Urothelial Carcinoma" on May 9th;  "A Clinical Trial of Adjuvant Nivolumab Following Chemoradiation in Localized Muscle-Invasive Urothelial Cancer," on May 12th; and "Trimodality Therapy Compared to Radical Cystectomy for Muscle-Invasive Bladder Cancer," on May 19th. 

In the news article "Targeting ESR1 Mutations Early May Improve Outcomes in Breast Cancer," EIPM Scientific Director Dr. Massimo Cristofanilli discusses his new research published in the NEJM(see below) on the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer, with Cure on June 3rd. This paper also generated news coverage by NBC News on June 1st; in Healio on June 1st; and in The Mirage News on June 1st. 

Research published in March in NPJ Digital Medicine by our Chief Research Officer Dr. Bishoy Faltas was explored on a new May 12th article, "Deep Learning Helps Predict Treatment Response in Muscle-Invasive Bladder Cancer," published by NewYork-Presbyterian's Advancesnews site. 

"AI, Cancer, and HIV: An interview with Dr. Olivier Elemento," was featured in the the May 2025 issue ofamfAR INNOVATIONS.


Events
Recent research by our Clinical Director Dr. Cora N. Sternberg and colleagues was featured in the poster, "Long-term safety of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC): 7-year follow-up from the largest global prospective study," presented at the 2025 ASCO Annual Meeting. 


Publications
"First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer," was published in The New England Journal of Medicine on June 1st by EIPM Scientific Director Dr. Massimo Cristofanilli and colleagues. 

"Comprehensive evaluation of phosphoproteomic-based kinase activity inference," was published in Nature Communications on May 22nd by EIPM's Dr. Tomer Yaron and colleagues.

"Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models," was published in the British Journal of Cancer on May 13th by Dr. Benjamin D. Hopkins and colleagues. 

"Clinical Bioinformatician Body of Knowledge—Bioinformatics and Software Core," was published in The Journal of Molecular Diagnostics by Dr. Andrea Sboner from the Pathology and Laboratory Medicine department and the EIPM's Director of Informatics and Computational Biology.

"Spatial–Temporal Diversity of Extrachromosomal DNA Shapes Urothelial Carcinoma Evolution and the Tumor Immune Microenvironment," was published in Cancer Discovery on May 7th by our Chief Research Officer Dr. Bishoy Faltas and colleagues. 

"Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma," was published in Molecular Cancer Research on May 2nd by Bhavneet Bhinder and Director Olivier Elemento, Ph.D. with Dr. Ethel Cesarman from the Pathology and Laboratory Medicine department. 

"Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node–only Disease," was published in European Urology on June 3rd by our Clinical Director Dr. Cora N. Sternberg and colleagues.

"AutoRadAI: a versatile artificial intelligence framework validated for detecting extracapsular extension in prostate cancer," was published in Biology Methods and Protocols on April 26th by Dr. Iman Hajirasouliha and colleagues. 

"Three-dimensional genome landscape of primary human cancers," was published in Nature Genetics on May 12th by Dr. Ekta Khurana and colleagues. 

"Epigenomic analysis identifies DTP subpopulation using HOPX to develop targeted therapy resistance in lung adenocarcinoma," was published in iScience on May 16th by Dr. Benjamin D. Hopkins and colleagues. 

"An atlas of bacterial serine-threonine kinases reveals functional diversity and key distinctions from eukaryotic kinases," was published in Science Signaling on May 6th by Dr. Tomer M. Yaron-Barir and colleagues. 

"Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation," was published in Cancer Cell on May 12th by Michael Sigouros and colleagues. 

#  #  #